Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 11Genitourinary 6Breast 5Gastrointestinal 4Thoracic 3Head & Neck 3Dermatologic 3Sarcoma 1Lymphoid 1

Conditions

Sarcoma 8Melanoma 3Hemangiosarcoma 3Breast Neoplasms 3Prostatic Neoplasms 2Osteosarcoma 2Neoplasms 2Leiomyosarcoma 2Carcinosarcoma 2Carcinoma, Endometrioid 2Vascular Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Neoplasms 1Testicular Neoplasms 1Tertiary Lymphoid Structures 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Pathologic Complete Response 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1Liposarcoma 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Hemangioendothelioma, Epithelioid 1

Interventions

pembrolizumab 4Specimen Handling 3Magnetic Resonance Spectroscopy 3tislelizumab 2aflibercept 2Surveys and Questionnaires 2Radiotherapy 2Gene Expression Profiling 2Fentanyl 2Docetaxel 2Diet Therapy 2Blood Specimen Collection 2Biopsy 2trastuzumab deruxtecan 1toripalimab 1spartalizumab 1sargramostim 1rucaparib 1pegfilgrastim 1pazopanib 1olaparib 1milademetan 1entinostat 1durvalumab 1ciforadenant 1ceralasertib 1cemiplimab 1avelumab 1X-Rays 1Trastuzumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × durvalumab × Sarcoma × Clear all
NCT04065269 2026-02-20

ATARI

Institute of Cancer Research, United Kingdom

Phase 2 Active not recruiting
174 enrolled
GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡